BioMarin Pharmaceutical (BMRN) Osake Kurssi

Biomarin Pharmaceutical Inc primarily operates in the biopharmaceutical industry.

The main competitors of Biomarin Pharmaceutical Inc in the market are competitive biotechnology and pharmaceutical companies such as Alexion Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Ultragenyx Pharmaceutical Inc. These companies operate in the same industry and focus on developing innovative therapies for rare genetic diseases and conditions, just like Biomarin Pharmaceutical Inc. These competitors pose challenges to Biomarin Pharmaceutical Inc's market share, as they constantly strive to advance their own treatments and attract patients and healthcare professionals. However, Biomarin Pharmaceutical Inc maintains a strong position in the market with its portfolio of cutting-edge therapies and ongoing research and development efforts.

Biomarin Pharmaceutical Inc, founded in 1997, is a globally recognized biotechnology company headquartered in California. Specializing in developing innovative therapies for rare genetic diseases, Biomarin has established itself as a leader in the field. With a commitment to scientific excellence, the company has gained significant expertise and has successfully brought numerous groundbreaking treatments to market. Biomarin's dedication to improving the lives of patients with rare disorders has made it a trusted name in the pharmaceutical industry. With its strong track record of developing transformative therapies, Biomarin continues to make valuable contributions towards addressing unmet medical needs.

Some significant milestones achieved by Biomarin Pharmaceutical Inc include obtaining FDA approval for several of its innovative therapies, such as Kuvan for Phenylketonuria (PKU) and Vimizim for Morquio A syndrome. The company also successfully launched Naglazyme for Maroteaux-Lamy syndrome and Palynziq for phenylketonuria patients. Biomarin Pharmaceutical Inc has consistently demonstrated its commitment to research and development, focusing on rare genetic diseases. With its dedication to advancing medical treatments, the company continues to make groundbreaking discoveries, improving the lives of patients worldwide.

Biomarin Pharmaceutical Inc is primarily present in various countries and regions worldwide. The company has a global presence and operates in key pharmaceutical markets. Biomarin's significant presence can be observed in the United States, where its headquarters are located. Additionally, Biomarin Pharmaceutical Inc also maintains a strong presence in Europe, including countries like the United Kingdom, Germany, France, and Italy. Furthermore, the company has established a foothold in Asia, with operations in Japan and China. With its extensive international reach, Biomarin Pharmaceutical Inc continues to expand its market presence and deliver innovative therapies to patients globally.

Biomarin Pharmaceutical Inc is dedicated to improving the lives of patients with rare genetic diseases. The company's corporate philosophy revolves around innovation, collaboration, and integrity. Biomarin strives to develop transformative therapies that address unmet medical needs and provide hope for patients and their families. With a strong commitment to research and development, Biomarin focuses on advancing cutting-edge technologies and delivering life-changing treatments. By partnering with healthcare professionals, patient advocacy groups, and regulatory agencies, Biomarin aims to make a meaningful impact in the field of rare diseases. With its tireless pursuit of excellence, Biomarin Pharmaceutical Inc sets itself apart as a leader in the biopharmaceutical industry.

Analyytikot asettavat tällä hetkellä BioMarin Pharmaceutical-osakkeelle keskimääräisen tavoitehinnan 91,81 USD (mediaani: 97,50 USD), mikä merkitsee +60,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 35 analyytikkoarvioon.

BioMarin Pharmaceutical Analyytikkojen kursstavoitteet 2026

35 analyytikkoa arvioi tällä hetkellä BioMarin Pharmaceutical-osaketta: 27 suosittaa ostoa, 8 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BioMarin Pharmaceutical-yhtiöltä 3,92 Mrd. USD liikevaihtoa ja 3,53 USD osakekohtaista tulosta.

BioMarin Pharmaceutical Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla BioMarin Pharmaceutical-osake noteerataan hintaan 49,97 EUR (56,12 USD).

BioMarin Pharmaceutical-osake (BMRN) on listattuna 10 pörssissä, muun muassa: NASDAQ (BMRN), London (0HNC.L), SIX (Zürich) (BM8.SW), XETRA (BM8.DE), Frankfurt (BM8.F), München (BM8.MU), Düsseldorf (BM8.DU), Wien (BMRN.VI).

BioMarin Pharmaceutical Inc is a biotechnology company that develops and markets medications for the treatment of rare genetic diseases. The company focuses on genetics, enzymology, and biology and is dedicated to discovering and developing novel therapies for rare diseases that are often untreated or poorly treated. The company was founded in 1997 and is headquartered in San Rafael, California. BioMarin Pharmaceutical Inc currently operates in over 40 countries and employs over 3,000 people worldwide. BioMarin Pharmaceutical Inc's business model is based on research, development, and marketing of therapeutics for rare diseases. The company is divided into four business segments: therapeutic enzymes, protein and peptide therapies, gene therapies, and neuromuscular diseases. Each of these segments aims to treat specific diseases that have either no or very limited treatment options. The first business segment, therapeutic enzymes, focuses on the development of novel therapeutic options for rare genetic diseases caused by enzyme deficiencies. The main products in this segment are Kuvan and Naglazyme. Kuvan is a medication used to treat phenylketonuria (PKU), a rare disorder that affects the metabolism of phenylalanine. Naglazyme is an enzyme used to treat mucopolysaccharidosis VI (MPS VI), which affects bone growth, metabolism, and the central nervous system. The second business segment, protein and peptide therapies, develops treatments based on proteins and peptides to treat rare diseases. The products produced in this segment include Vimizim, Brineura, and Palynziq. Vimizim is a therapy for the treatment of Morquio A syndrome, a rare disorder that affects bone growth. Brineura is an enzyme replacement therapy for the treatment of a form of neuronal ceroid lipofuscinosis. Palynziq is an injectable enzyme replacement therapy for the treatment of acute enzyme deficiencies in adults with phenylketonuria (PKU). The third business segment, gene therapies, specializes in developing treatment options for genetic changes related to diseases. The company is currently developing a gene therapy for hemophilia A, a chronic genetic disorder caused by a missing clotting factor protein. The fourth business segment, neuromuscular diseases, develops therapies for the treatment of rare muscular diseases. The company is currently working on developing therapies for infantile and childhood diseases such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). An example product in this segment is BMN 250, a gene therapy for DMD. Overall, BioMarin Pharmaceutical Inc provides therapeutic treatment options for patients suffering from rare and severe diseases. By consistently advancing in research and development, the company has been able to expand its market position in this niche. The company is particularly focused on achieving a long-term goal: improving the quality of life for patients by developing treatment options for diseases that currently have insufficient treatment options.

odotettu liikevaihto BioMarin Pharmaceutical on 3,92 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto BioMarin Pharmaceutical on 697,34 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

BioMarin Pharmaceutical:n hinta-voitto-suhde (P/E) on tällä hetkellä 15,89. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BioMarin Pharmaceutical-osakkeen arvostusta.

BioMarin Pharmaceutical:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,83. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BioMarin Pharmaceutical-osakkeen arvostuskennuslukuna.

BioMarin Pharmaceutical:n Eulpool-laatuscore on 6/10.

BioMarin Pharmaceutical:n ISIN on US09061G1013. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

BioMarin Pharmaceutical:n WKN on 924801. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

BioMarin Pharmaceutical:n ticker on BMRN. Tämä pörssinoteeraus käytetään BioMarin Pharmaceutical-osakkeiden kauppaan pörssissä.